The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology
Abstract
Anemia resulting from cancer or its treatment is an important clinical problem increasingly treated with the recombinant hematopoietic growth factor erythropoietin. To address uncertainties regarding indications and efficacy, the American Society of Clinical Oncology and the American Society of Hematology developed an evidence-based clinical practice guideline for the use of epoetin in patients with cancer. The guideline panel found good evidence to recommend use of epoetin as a treatment option for patients with chemotherapy-associated anemia with a hemoglobin (Hgb) concentration below 10 g/dL. Use of epoetin for patients with less severe anemia (Hgb level below 12 g/dL but never below 10 g/dL) should be determined by clinical circumstances. Good evidence from clinical trials supports the use of subcutaneous epoetin thrice weekly (150 U/kg) for a minimum of 4 weeks. Less strong evidence supports an alternative weekly (40 000 U/wk) dosing regimen, based on common clinical practice. With either administration schedule, dose escalation should be considered for those not responding to the initial dose. In the absence of response, continuing epoetin beyond 6-8 weeks does not appear to be beneficial. Epoetin should be titrated once the hemoglobin concentration reaches 12 g/dL. Evidence from one randomized controlled trial supports use of epoetin for patients with anemia associated with low-risk myelodysplasia not receiving chemotherapy; however, there are no published high-quality studies to support its use for anemia in other hematologic malignancies in the absence of chemotherapy. Therefore, for anemic patients with hematologic malignancies it is recommended that physicians initiate conventional therapy and observe hematologic response before considering use of epoetin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Schulz (1995) · doi:10.1001/jama.1995.03520290060030 · Cited by 5,634
Moher, D., Pham, B., Jones, A., Cook, D. J., Jadad, A. R., Moher, M., Tugwell, P., & Klassen, T. P. (1998) · The Lancet · doi:10.1016/s0140-6736(98)01085-x · Cited by 3,560
An Assessment of Clinically Useful Measures of the Consequences of Treatment
Laupacis, A., Sackett, D. L., & Roberts, R. S. (1988) · New England Journal of Medicine · doi:10.1056/nejm198806303182605 · Cited by 1,681
Cheung, W. K., Goon, B. L., Guilfoyle, M. C., & Wacholtz, M. C. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90072-8 · Cited by 112
Cited by
Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization
Heeschen, C., Aicher, A., Lehmann, R., Fichtlscherer, S., Vasa, M., Urbich, C., Mildner-Rihm, C., Martin, H., Zeiher, A. M., & Dimmeler, S. (2003) · Blood · doi:10.1182/blood-2003-01-0223 · Cited by 845
Clinical practice guideline: Red blood cell transfusion in adult trauma and critical care*
Napolitano, L. M., Kurek, S., Luchette, F. A., Corwin, H. L., Barie, P. S., Tisherman, S. A., Hebert, P. C., Anderson, G. L., Bard, M. R., Bromberg, W., et al. (2009) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181b39f1b · Cited by 551
Lineage-Specific Hematopoietic Growth Factors
Kaushansky, K. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052706 · Cited by 509
Red blood cell transfusion in clinical practice
Klein, H. G., Spahn, D. R., & Carson, J. L. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61197-0 · Cited by 487
Molecular Biology of Erythropoietin
JELKMANN, W. (2004) · Internal Medicine · doi:10.2169/internalmedicine.43.649 · Cited by 383
Metadata
- Authors
- Rizzo, J. D.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2002-08-29
- Volume
- 100
- Issue
- 7
- Pages
- 2303-2320
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2112833469
- Cited by
- 224
- References
- 4
- FWCI
- 13.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. https://app.cochat.ai/papers/10.1182/blood-2002-06-1767
- The paper
- Rizzo, J. D. (2002). Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood. https://doi.org/10.1182/blood-2002-06-1767
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.